Fever Screening News
-
Histoplasmosis Infection Risks for Workers & Vulnerable Populations
ScienceNews published an article last year about the spread of three types of fungi that can cause serious lung diseases. One of these was Histoplasma which causes histoplasmosis, an infection once mainly found in the Midwest, but in more recent times infections have been recorded in at least 47 states. Histoplasma capsulatum lives in the environment, particularly in soil or other materials ...
-
Histoplasma Infection Risks for Workers and Vulnerable Populations in Puerto Rico
Histoplasmosis is the name of an infection caused by a fungus known as Histoplasma capsulatum. The fungus lives in the environment, particularly in soil or other materials that contain large amounts of bird or bat droppings. Outbreaks of histoplasmosis have been recorded in Puerto Rico, as well as in the Dominican Republic and other parts of the Caribbean. The Centers for Disease Control and ...
-
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Orginally published by https://www.globenewswire.com/ Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Emergent will begin the planning phase, the first ...
-
FireGene's Monkeypox Virus Nucleic Acid Detection Kit (Real-time PCR Method) Receives CE-IVDD Certification
FireGene announces that its Monkeypox Virus Nucleic Acid Detection Kit (Real-time Fluorescent PCR Method) has recently obtained CE-IVDD approval. This RT-PCT kit can be used to detect suspected cases of MPV infection. Rash fluid, nasopharyngeal swabs, pharyngeal swabs, and serum samples are applicable for the test. The test result is available in 40 minutes after sample collection. This kit is ...
By FireGene
-
Covid-19 or Seasonal Allergy: How to differentiate?
COVID-19 and seasonal allergies have many of the same signs and symptoms. However, there are some differences, knowing them can help you seek out the right treatments to provide effective relief. Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate ...
-
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
Both studies fully recruited, with data from the Dengue Fever study anticipated in the summer Preclinical data for Emergex’s Coronavirus vaccine candidate suggests that it could provide heterologous immunity to viruses from the same family Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major ...
-
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
Emergex’s CD8+ T cell Adaptive Vaccine platform will now be used to generate a tularemia vaccine candidate that provides a cytotoxic (killing of infected cells) CD8+ T cell response and offers a means for rapid development suitable for deployment as a medical countermeasure. Emergex’s ongoing Phase I clinical trials on vaccine candidates for Dengue Fever and COVID-19 are evaluating ...
-
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. ATCC is a non-profit ...
-
Virgin Islands Department of Health Confirms Multiple Cases of Legionnaires’ Disease
Last month, the United States Virgin Islands Department of Health announced that cases of Legionnaires’ disease had been detected in both St. Thomas and St. Croix. People can develop this disease by breathing in a mist or water droplets contaminated with a type of bacteria known as Legionella. Tragically, the Centers for Disease Control and Prevention (CDC) reports that about 1 in 10 people ...
-
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic Priming T cell Adaptive Vaccines, today announces that it has been awarded a £490,525 grant by the UK government’s Department of Health and Social Care (‘DHSC’) to advance a synthetic T ...
-
Clinical Data Published in Clinical Microbiology and Infection Support Use of MeMed’s Test in Reducing Antibiotic Overuse in Children
The study demonstrated the test’s high performance in distinguishing between bacterial and viral infection Incorporated a broad pediatric population presenting with fever without source and respiratory tract infection MeMed’s test outperformed existing biomarkers of infection MeMed, a leader in the emerging field of advanced hostresponse technologies, today announces positive ...
By MeMed
-
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
Emergex confirms that the viral peptides in its COVID-19 vaccine candidate are present in the following sequenced variants, including B.1.1.7(Alpha, UK), B.1.1.28 (Gamma, Brazil) B.1.351 (Beta, South Africa), B.1.429 (South Carolina) B.1.617.2 (Delta, India), B.1.1.529 (Omicron, multiple countries) – meaning that no impact on the efficacy of the vaccine is anticipated Emergex’s ...
-
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
Synthetic vaccine designed to prime T-Cells to rapidly remove viral-infected cells from the body after infection May offer broad immunity against SARS-CoV-1 and all SARS-CoV-2 variants and provide long-lasting immunity that does not require seasonal booster vaccines Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global ...
-
5 Benefits of Using Electronic Contact Tracing In Healthcare
Contact tracing is an important strategy for controlling disease. Hospitals that can quickly identify who was exposed, where they went, and who they interacted with can cut down on transmission and significantly slow the spread of costly infections. Unfortunately, many hospitals and healthcare settings still rely on manual efforts to contact trace, which can be time-intensive and prone to error. ...
By BioVigil
-
Exhibition guidelines for health and safety
Exhibition guidelines for health and safety Wearing face mask is required when entering and during the exhibition. To ensure exhibitors and visitors health, one with temperature above 37.5°C, admittance would be declined. Exhibition will be on a real name basis, visitor with 'Admission QR Code', or cooperate with each exhibition's mandatory information before entering. Individuals ...
-
Enesi Pharma’s ImplaVax-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical ...
-
Atomwise Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021
Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2021. Atomwise was recognized for its unmatched AI platform, AtomNet®?, as well as its growing pipeline and portfolio of partnerships and joint ventures tackling some of the most ...
-
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute ...
-
EPA Announces Proposed Updates to List of Pests of Significant Health Importance
On November 4, 2020, the U.S. Environmental Protection Agency (EPA) published a notice in the Federal Register announcing the release of an updated list of pests of significant health importance for public review and comment. 85 Fed. Reg. 70146. EPA, in coordination with the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Agriculture (USDA), identifies pests of ...
-
COVID-19 Business Update #4
Following on from the announcement made by the Prime Minister on Saturday 31st October 2020 regarding an England-wide lockdown, we wanted to update you on what Cirrus Research is continuing to do to ensure the safety of our teams, whilst providing you with the equipment and service you need. The key message is that Cirrus Research will remain fully operational throughout the proposed four-week ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you